Division of Nephrology and Hypertension

October 29, 2015

Inflammation, obesity and diabetes

Vanderbilt study adds to the mounting role for inflammatory signaling in obesity.

By Leigh MacMillan
October 22, 2015

Study sheds light on side effects of COX-2 drugs

A team of Vanderbilt University Medical Center scientists are closer to understanding why COX-2 inhibitors — drugs that relieve arthritis pain and inflammation without the gastrointestinal side effects of other painkillers — cause heart problems in some patients.

Now

By Bill Snyder
September 17, 2015

Study shows lower systolic BP targets reduce death risk

The initial results of a landmark clinical trial sponsored by the National Institutes of Health (NIH) indicate lowering systolic blood pressure below a commonly recommended target significantly reduces rates of cardiovascular events and lowers risk of death in a group of adults 50 years and older.

By Kathy Whitney
kidney x-ray
August 13, 2015

Million Veteran Program data spurs research in pharmacogenomics of kidney disease

A team of Vanderbilt and Nashville VA researchers, led by Adriana Hung, M.D., MPH, has been awarded a grant from the U.S. Department of Veterans Affairs to use the Million Veteran Program (MVP) data to conduct diabetes research.

By Kathy Whitney
June 11, 2015

Study: Why one kidney can work as well as two

Vanderbilt University researchers have come closer to solving a mystery that has puzzled scientists for more than a century: after the loss of one kidney, what causes the growth of the remaining kidney to take up the slack?

By Bill Snyder
January 8, 2015

Integrin discovery may lead to better lung treatments

Vanderbilt University researchers have made an important advance in understanding lung development, which one day could lead to improvements in treating lung disease in premature infants and adults.

By Bill Snyder
October 30, 2014

NIH grant spurs diabetic nephropathy research

Diabetic nephropathy, or kidney disease caused by diabetes, is a major source of morbidity and mortality. In the United States, more than 30 percent of patients receiving either dialytic therapy or renal transplantation have end stage renal disease as a result of diabetic nephropathy.
By Kathy Whitney
July 31, 2014

Photo: Summer research conference

Undergraduates from across the country attended a summer research conference at Vanderbilt this week sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.
By VUMC News and Communications
July 10, 2014

Molecular ‘chat’ holds kidney fibrosis clues

A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process.
By Leigh MacMillan
June 26, 2014

VU study shows common diabetes drug can slow chronic kidney disease progression

Vanderbilt investigators have demonstrated in two studies that metformin-based treatments delay the onset and progression of chronic kidney disease (CKD) compared with other treatments for diabetes.
By Kathy Whitney
May 29, 2014

New center dedicated to kidney disease

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.
By Kathy Whitney
May 8, 2014

Nighttime dialysis treatments available

Vanderbilt University Medical Center, committed to providing multiple options to patients who have kidney disease, recently began offering nocturnal in-center hemodialysis, which allows patients to receive treatment at night while they sleep.
By Kathy Whitney
February 7, 2014

New direction for treating lung cancer

Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.
By Leigh MacMillan
1 … 5 6 7 8 9